These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23521147)

  • 1. Uninterrupted warfarin therapy for the implantation of cardiac rhythm devices.
    Barold SS; Giudici M; Herweg B
    Pacing Clin Electrophysiol; 2013 May; 36(5):537-40. PubMed ID: 23521147
    [No Abstract]   [Full Text] [Related]  

  • 2. Perioperative anticoagulation for patients with mechanic heart valve(s) undertaking pacemaker implantation.
    Cheng M; Hua W; Chen K; Pu J; Ren X; Zhao X; Liu Z; Wang F; Chen X; Zhang S
    Europace; 2009 Sep; 11(9):1183-7. PubMed ID: 19666639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices.
    Ghanbari H; Phard WS; Al-Ameri H; Latchamsetty R; Jongnarngsin K; Crawford T; Good E; Chugh A; Oral H; Bogun F; Morady F; Pelosi F
    Am J Cardiol; 2012 Nov; 110(10):1482-8. PubMed ID: 22906894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implanting cardiac rhythm devices during uninterrupted warfarin therapy: a prospective, single center experience.
    Crosato M; Calzolari V; Franceschini Grisolia E; Daniotti A; Baldessin F; Mantovan R; Olivari Z
    J Cardiovasc Med (Hagerstown); 2015 Jul; 16(7):503-6. PubMed ID: 25022924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Perioperative Anticoagulation for Device Implantation.
    Stewart MH; Morin DP
    Card Electrophysiol Clin; 2018 Mar; 10(1):99-109. PubMed ID: 29428146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between warfarin, aspirin, and clopidogrel continuation in the peri-procedural period and the incidence of hematoma formation after device implantation.
    Thal S; Moukabary T; Boyella R; Shanmugasundaram M; Pierce MK; Thai H; Goldman S
    Pacing Clin Electrophysiol; 2010 Apr; 33(4):385-8. PubMed ID: 20059711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of continued-warfarin versus heparin-bridging therapy during pacemaker and defibrillator surgery.
    Coyle D; Coyle K; Essebag V; Birnie DH; Ahmad K; Toal S; Sapp J; Healey JS; Verma A; Wells G; Krahn AD
    J Am Coll Cardiol; 2015 Mar; 65(9):957-9. PubMed ID: 25744016
    [No Abstract]   [Full Text] [Related]  

  • 8. Implantation of cardiac rhythm devices without interruption of oral anticoagulation compared with perioperative bridging with low-molecular weight heparin.
    Tischenko A; Gula LJ; Yee R; Klein GJ; Skanes AC; Krahn AD
    Am Heart J; 2009 Aug; 158(2):252-6. PubMed ID: 19619702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin.
    Kovacs MJ; Kearon C; Rodger M; Anderson DR; Turpie AG; Bates SM; Desjardins L; Douketis J; Kahn SR; Solymoss S; Wells PS
    Circulation; 2004 Sep; 110(12):1658-63. PubMed ID: 15364803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the optimal level of anticoagulation in adult patients receiving warfarin following implantation of a mechanical prosthetic mitral valve?
    Bayliss A; Faber P; Dunning J; Ronald A
    Interact Cardiovasc Thorac Surg; 2007 Jun; 6(3):390-6. PubMed ID: 17669876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of warfarin anticoagulation in pregnant patients with mechanical heart valve prostheses.
    Della Corte A; De Feo M; Romano G; Amarelli C; De Santo LS; Nappi G; Scardone M; Cotrufo M
    J Heart Valve Dis; 2004 May; 13 Suppl 1():S90. PubMed ID: 15225015
    [No Abstract]   [Full Text] [Related]  

  • 12. Peri-operative anticoagulant therapy--the case for an uninterrupted dose-adjusted warfarin regimen in the high-risk patient.
    Franz RC
    S Afr J Surg; 2006 Aug; 44(3):84, 86. PubMed ID: 16958233
    [No Abstract]   [Full Text] [Related]  

  • 13. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H; Selçuk MT; Maden O
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm?
    ElBardissi AW; DiBardino DJ; Chen FY; Yamashita MH; Cohn LH
    J Thorac Cardiovasc Surg; 2010 May; 139(5):1137-45. PubMed ID: 20303508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risk of thromboembolism in heart failure: does it merit anticoagulation therapy?
    Shantsila E; Lip GY
    Am J Cardiol; 2011 Feb; 107(4):558-60. PubMed ID: 21295173
    [No Abstract]   [Full Text] [Related]  

  • 16. Implantation of cardiac rhythm devices during concomitant anticoagulation or antiplatelet therapy.
    Ramirez A; Wall TS; Schmidt M; Selzman K; Daccarett M
    Expert Rev Cardiovasc Ther; 2011 May; 9(5):609-14. PubMed ID: 21615324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabigatran: safer, more effective and easier to use than warfarin.
    Cardiovasc J Afr; 2009; 20(5):311-2. PubMed ID: 19907807
    [No Abstract]   [Full Text] [Related]  

  • 18. Do not stop the warfarin until ..
    Cakulev I; Waldo AL
    J Am Coll Cardiol; 2010 Feb; 55(8):744-6. PubMed ID: 20170811
    [No Abstract]   [Full Text] [Related]  

  • 19. Uninterrupted anticoagulation during pacemaker or defibrillator surgery.
    BMJ; 2013 May; 346():f3087. PubMed ID: 23678094
    [No Abstract]   [Full Text] [Related]  

  • 20. Oral anticoagulation in patients with mechanical valve prostheses: evolving protocols with new generation devices.
    Cotrufo M; De Feo M; De Santo LS; Della Corte A; Scardone M; Costanza S
    Ital Heart J; 2005 May; 6(5):401-4. PubMed ID: 15934413
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.